DocWire News Editors

DocwireNews

Patients with chronic lymphocytic leukemia (CLL) who have mild residual lymphadenopathy are more likely to have a partial response (PR) after treatment with venetoclax-obinutuzumab (VenG), a study found. This finding provides a potential prognostic indicator for poor prognosis in patients VenG-treated patients with CLL.Results of this study were presented by Othman Al-Sawaf, MD, of the University Hospital Cologne, at the 62nd American Society of Hematology Annual Meeting &amp; Exposition. In the study, Dr. Al-Sawaf and colleagues randomly assigned 432 patients with previously untreated CLL to 12 cycles of venetoclax with six cycles of obinutuzumab (n=216) or 12 cycles of chlorambucil with six cycles of obinutuzumab (n=216). The primary endpoint of the study was progression-free survival (PFS).Over the median follow up of 39.6 months, approximately 45.8% of patients in the VenG arm experienced a complete response (CR), whereas 36.1% of patients had a PR at the end of treatment. Around 55.2% of patients with PR and undetectable minimal residual disease (MRD) had a PR because of residual lymphadenopathy &gt;15 mm and &lt;72 mm.No bone marrow biopsy had been performed in 18 patients. Due to the missing bone marrow biopsy, the investigators were unable to identify a CR.A total of 90 patients with a CR at the end of treatment had undetectable MRD levels in peripheral blood, and 13 of these patients were MRD-positive. There was no difference between patients with undetectable MRD compared with patients with undetectable MRD and CR in terms of PFS. In contrast, patients with undetectable MRD and PR had a more prolonged PFS compared with patients with detectable MRD and CR.The researchers concluded that their data show patients with a PR following VenG treatment experience a similar outcome as patients with CR when undetectable MRD is achieved.

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Residual Lymphadenopathy Associated with Partial Response After VenG in CLL

ASH Annual Meeting 2020

Patients with chronic lymphocytic leukemia (CLL) who have mild residual lymphadenopathy are more likely to have a partial response (PR) after treatment with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe